Redsense Medical AB (publ), a leader in innovations for safety and monitoring of the venous access in dialysis treatment, announces that board member Lena Oswald has chosen to leave her post due to personal reasons.
The company thanks Lena Oswald for her efforts during her time serving the board and wishes her every success in her future undertakings.
For more information
Jennie Kardell, CEO
Telephone: +46 72-171 1264
E-mail: jennie.kardell (at) redsensemedical.com
Redsense Medical AB (publ), 556646-4862
About Redsense Medical
Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovation used for monitoring and alarm in the case of blood leakage in connection with a hemodialysistreatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company’s technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector. The Redsense Medical share is listed on Spotlight Stock Market (REDS) and traded on OTCQX (RDSNF) in the US.
